I. Perez, Sara Taveras Alam, Gabriel A. Hernandez, Rhea Sancassani
{"title":"癌症治疗相关心功能障碍:临床医生综述","authors":"I. Perez, Sara Taveras Alam, Gabriel A. Hernandez, Rhea Sancassani","doi":"10.1177/1179546819866445","DOIUrl":null,"url":null,"abstract":"Cancer therapy-related cardiac dysfunction (CTRCD) is one of the most feared and undesirable side effects of chemotherapy, occurring in approximately 10% of the patients. It can be classified as direct (dose-dependent vs dose-independent) or indirect, either case being potentially permanent or reversible. Risk assessment, recognition, and prevention of CTRCD are crucial.","PeriodicalId":10419,"journal":{"name":"Clinical Medicine Insights. Cardiology","volume":"5 1","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"91","resultStr":"{\"title\":\"Cancer Therapy-Related Cardiac Dysfunction: An Overview for the Clinician\",\"authors\":\"I. Perez, Sara Taveras Alam, Gabriel A. Hernandez, Rhea Sancassani\",\"doi\":\"10.1177/1179546819866445\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Cancer therapy-related cardiac dysfunction (CTRCD) is one of the most feared and undesirable side effects of chemotherapy, occurring in approximately 10% of the patients. It can be classified as direct (dose-dependent vs dose-independent) or indirect, either case being potentially permanent or reversible. Risk assessment, recognition, and prevention of CTRCD are crucial.\",\"PeriodicalId\":10419,\"journal\":{\"name\":\"Clinical Medicine Insights. Cardiology\",\"volume\":\"5 1\",\"pages\":\"\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2019-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"91\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Medicine Insights. Cardiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/1179546819866445\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine Insights. Cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/1179546819866445","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
Cancer Therapy-Related Cardiac Dysfunction: An Overview for the Clinician
Cancer therapy-related cardiac dysfunction (CTRCD) is one of the most feared and undesirable side effects of chemotherapy, occurring in approximately 10% of the patients. It can be classified as direct (dose-dependent vs dose-independent) or indirect, either case being potentially permanent or reversible. Risk assessment, recognition, and prevention of CTRCD are crucial.